Study to Evaluate the Efficacy of an Avocado Dietary Supplement (METAVO-ONE)

A Study to Evaluate the Efficacy of an Avocado Dietary Supplement to Support Healthy Weight and Blood Glucose Management

This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.

Study Overview

• Status: Active, not recruiting
• Conditions: Overweight; Insulin Resistance; Metabolic Health
• Intervention / Treatment: Dietary supplement: Metavo Supplement; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89118
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be male or female
• Be aged between 18 and 70 years of age
• Be classified as overweight or obese with a BMI of ≥25.0 and ≤32 kg/m2.
• Have a stable weight defined as <10% change in body weight in three months prior to the study start date.
• Willing to follow the provided diet and exercise guidelines.
• Willing to not consume avocados throughout the trial and for two weeks prior to Baseline
• Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
• Willing to stop any products, any prescription medication, or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
• Willing to avoid introducing any new products or any new forms of prescription medication or supplements that target weight management, blood sugar control, and/or aim to improve insulin during the test period.
• Not currently partaking in another research study and will not be partaking in any other research study for the next 16 weeks and at any point during this study's duration.
• Must have someone available to take front and side profiles of the torso.
• Must have a smart phone or camera capable of taking photos of the torso.
• Resides in the United States.

Exclusion Criteria:

• Anyone with diagnosed Type I or Type II diabetes.
• Allergic to avocados
• Anyone with any allergies or sensitivities to any of the study product ingredients.
• Any women who are pregnant, breastfeeding, or trying to conceive
• Anyone unwilling to follow the study protocol.
• Has stopped using hormonal birth control in the past month.
• Anyone with a history of substance abuse.
• Anyone who is currently a smoker or has been a smoker in the past 6 months.
• Anyone with chronic health conditions that could impact participation in the study, such as oncological, psychiatric, metabolic, hypertension, or cardiovascular disorders, cancer, autoimmune disease, HIV, Hepatitis B, and/or C, kidney and/or liver, gastrointestinal, gastroesophageal reflux, blood/bleeding disorders, gout, or mental health disorders.
• Anyone who has had any major illness in the last 3 months.
• Anyone who drinks heavily (i.e., 8 or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men).
• Current use of prescribed medications as listed below: Weight loss prescription medication (within 3 months of baseline). Anticoagulants and coagulants (within 4 weeks of baseline).
• Anyone who has used any cannabis products (medical or recreational) in the past month.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Metavo Supplement Group; Participants in this group will receive the Metavo dietary supplement for 16 weeks.	Dietary supplement: Metavo Supplement; Participants will take 8 Intervention capsules per day (4 in the morning, 4 in the afternoon)
Placebo Comparator: Placebo Group; Participants in this group will receive placebo capsules that are visually matched to the Metavo supplement for 16 weeks.	Dietary supplement: Placebo; Participants will take 8 placebo capsules per day (4 in the morning, 4 in the afternoon)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Body Mass	Measured via Withings Smart Scale. Participants will weigh themselves daily for 3 consecutive days each week. If the first two values are similar, their average is used. If they differ by ≥10 lbs, the third value is used to determine the average.	Baseline through Week 16
Change in Average Blood Glucose	Change in average blood glucose levels measured using a Continuous Glucose Monitor (CGM). Average glucose will be calculated over each time period and the change from pre-baseline to Weeks 14-16 will be reported.	2 weeks before Baseline and Weeks 14-16
Change in Hemoglobin A1C (HbA1C)	Assessed via blood samples at Labcorp or via home phlebotomy.	Baseline and Week 16
Change in Fasting Insulin	Assessed via blood samples at Labcorp or via home phlebotomy.	Baseline and Week 16
Change in Lipid Panel	Includes Cholesterol, LDL, VLDL, HDL, and triglycerides. Measured via Labcorp or home phlebotomy.	Baseline and Week 16
Change in hs-CRP	High-sensitivity C-reactive protein measured via Labcorp or home phlebotomy.	Baseline and Week 16
Change in Fasting GLP-1 Levels	Only measured in the home phlebotomy subgroup using InterScience Institute lab testing.	Baseline and Week 16
Change in Waist Circumference	Measured with a tape measure.	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Time in Range (TIR)	Change in percentage of time that glucose levels are within the target range, measured using a CGM. TIR will be computed as the percentage of total CGM readings within the target range during the specified time periods.	2 weeks before Baseline and Weeks 14-16
Change in Time Below Range (TBR)	Change in percentage of time that glucose levels are below the target range, measured using a CGM. TBR will be calculated as the percentage of total CGM readings below the target range.	2 weeks before Baseline and Weeks 14-16
Change in Time Above Range (TAR)	Change in percentage of time that glucose levels are above the target range, measured using a CGM. TAR will be calculated as the percentage of total CGM readings above the target range.	2 weeks before Baseline and Weeks 14-16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Quality of Life	Evaluated using the Short Form-12 (SF-12) questionnaire.	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Physical Activity	Evaluated using the Godin Leisure-Time Exercise Questionnaire (GLTE).	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Eating Habits	Evaluated using the Three-Factor Eating Questionnaire - Revised 21 (TFEQ-R21).	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Food Cravings	Evaluated using the Food Craving Questionnaire - Trait reduced (FCQ-T reduced).	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Self-Reported Mood, Energy, and Health	Participants report changes in energy levels, weight perception, mood, and general well-being.	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Change in Total Muscle Mass (kg)	Total skeletal muscle mass measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).	Weekly from Baseline to Week 16
Change in Total Body Fat Mass (kg)	Total weight of body fat measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).	Weekly from Baseline to Week 16
Change in Bone Mass (kg)	Estimated weight of bone mineral content in kilograms, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).	Weekly from Baseline to Week 16
Change in Total Lean Mass (kg)	Total fat-free mass (including muscle, bone, and water) measured in kilograms using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).	Weekly from Baseline to Week 16
Change in Total Body Water Percentage (%)	Total body water as a percentage of total body weight, measured using a Withings smart scale via Bioelectrical Impedance Analysis (BIA).	Weekly from Baseline to Week 16
Change in Visceral Fat Index	An indexed score representing the amount of visceral fat (the fat surrounding internal organs) measured via a Withings smart scale. This index typically ranges from 1 to 20, where higher scores indicate higher visceral fat levels.	Weekly from Baseline to Week 16

Collaborators and Investigators

• Sponsor: SP Nutraceuticals Inc.
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2025
• Primary Completion (Estimated): January 1, 2026
• Study Completion (Estimated): January 1, 2026

Study Registration Dates

• First Submitted: December 6, 2025
• First Submitted That Met QC Criteria: January 14, 2026
• First Posted (Actual): January 21, 2026

Study Record Updates

• Last Update Posted (Actual): January 21, 2026
• Last Update Submitted That Met QC Criteria: January 14, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Weight Management; Glucose Metabolism; avocado
• Additional Relevant MeSH Terms: Nutrition Disorders; Metabolic Diseases; Overnutrition; Body Weight; Glucose Metabolism Disorders; Hyperinsulinism; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Signs and Symptoms; Overweight; Insulin Resistance
• Other Study ID Numbers: 20710

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No